Abstract: Disclosed is an electric power supply system, vehicle and method of operating a vehicle, wherein an electrical power supply system, in particular a traction system, of a vehicle, includes an energy storage module, an inverter, an electric machine, a receiving device adapted to receive an alternating electromagnetic field and to produce an alternating electric current by electromagnetic induction, and a passive electric circuit arrangement adapted to connect the inverter, the electric machine, and the receiving device, wherein the passive electric circuit arrangement includes a first transmission circuit for transferring electric energy between the receiving device and the electric machine, a second transmission circuit for transferring electric energy between the receiving device and the inverter, and a third transmission circuit for transferring electric energy between the inverter and the electric machine, wherein the passive electric circuit arrangement is designed such that at a given charging frequency,

Abstract: A spacer profile comprises: a basic body extending in a longitudinal direction of the profile with an outer contour which is substantially rectangular or trapezoid-shaped in a cross-section perpendicular to the longitudinal direction; the body comprising first and second transverse walls connected by a single side wall element and held at a pre-set spacing h; the side wall element ending with a first end at a first edge region of the first transverse wall and with a second end at a first edge region of the second transverse wall; the side wall element forming a path for thermal conduction from the first transverse wall to the second transverse wall, the path length approximately 1.1 or more times the spacing h; and comprising an anchoring protrusion held on the first transverse wall and extends from the body in a direction opposite to the second transverse wall.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: Disclosed is an electric power supply system, vehicle and method of operating a vehicle, wherein an electrical power supply system, in particular a traction system, of a vehicle, includes an energy storage module, an inverter, an electric machine, a receiving device adapted to receive an alternating electromagnetic field and to produce an alternating electric current by electromagnetic induction, and a passive electric circuit arrangement adapted to connect the inverter, the electric machine, and the receiving device, wherein the passive electric circuit arrangement includes a first transmission circuit for transferring electric energy between the receiving device and the electric machine, a second transmission circuit for transferring electric energy between the receiving device and the inverter, and a third transmission circuit for transferring electric energy between the inverter and the electric machine, wherein the passive electric circuit arrangement is designed such that at a given charging frequency,

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA). The invention further provides processes for the production of sustained-release pharmaceutical formulations and medical uses thereof.

Abstract: Sustained release formulations of triptorelin are provided.

Abstract: A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: A tricycle compound-polymer conjugate including a conjugate comprising a tricyclo compound and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.

Abstract: A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: The present invention relates to a process for the production of phyllosilicate platelets having a high aspect ratio, to a phyllosilicate platelet obtainable by the process according to the invention, to the use of phyllosilicate platelets according to the invention in the production of a composite material, of a flameproof barrier or of a diffusion harrier, and to a composite material comprising or obtainable using phyllosilicate platelets according to the invention.

Abstract: The present invention relates to a process for the production of non-swellable phyllosilicate tactoids, comprising A) producing a synthetic smectite of the formula I in a high-temperature-melt synthesis [Mn/Valenz]inter[MImMIIo]oct [MIII4]tet X10Y2??(I) B) if the interlayer cation M does not already have a hydration enthalpy from ?6282 to ?406 [kJ/mol], exchanging the interlayer cation M with a cation having a hydration enthalpy from ?6282 to ?406 [kJ/mol] by a cation-exchange method, C) dispersing phyllosilicate in an aqueous system, and D) exchanging M with a cation having a hydration enthalpy from ?405 to 0 [kJ/mol], by a cation-exchange method.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: A method of making a semiconductor device includes the steps of forming an oxide layer adjacent a semiconductor substrate, etching trenches within the oxide layer, depositing a copper layer to at least fill the etched trenches, and forming a copper arsenate layer on the deposited copper layer. The copper arsenate layer is then chemically mechanically polished. The copper layer may be deposited by at least one of electrodeposition, electroplating and chemical vapor deposition. The copper arsenate layer on the surface of the deposited copper layer inhibits oxidation and corrosion and stabilizes the microstructure of the deposited copper layer to thereby eliminate a need to subsequently anneal the deposited copper layer.

Abstract: An improved Schottky barrier connection is made to a desired region of a silicon wafer by implanting the region with ions to peak at a particular depth; depositing a suitable contact material, such as platinum, over such region; and then heating the wafer to react the platinum and the silicon such that the interface between the platinum-silicide and the silicon penetrates beyond the peak depth of the implant, some of the encountered dopant ions being accumulated at the advancing interface in snowplow fashion. There results a narrowed and concentrated layer of implanted ions localized just below the interface of the silicide and the silicon. The presence of this layer permits conduction in the forward direction at lower applied voltages without substantially degrading the reverse blocking characteristics.